Matthew Taylor
Stock Analyst at Jefferies
(3.43)
# 915
Out of 4,876 analysts
174
Total ratings
61.32%
Success rate
11.53%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $135 → $137 | $134.38 | +1.95% | 13 | Apr 17, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.19 | +5.71% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $74.38 | +38.48% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $78.21 | -10.50% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $313.08 | -28.77% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $86.02 | -11.65% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.43 | +5,044.03% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $168.21 | -28.07% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.78 | +403.60% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $18.94 | +137.59% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.49 | +1.19% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.29 | +331.24% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $8.58 | +179.72% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $393.55 | -12.34% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $91.46 | +42.14% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $256.43 | -10.31% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $18.43 | +8.52% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $52.17 | +62.93% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $58.60 | +27.99% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $255.16 | -3.98% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $30.39 | +104.01% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $119.47 | +75.78% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $11.08 | +8.30% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $86.33 | +44.79% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $106.53 | -53.06% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $533.71 | -60.65% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $45.75 | +109.84% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.96 | +257.14% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $170.86 | +55.68% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $9.78 | +63.60% | 2 | Jul 19, 2017 |
Abbott Laboratories
Apr 17, 2025
Maintains: Hold
Price Target: $135 → $137
Current: $134.38
Upside: +1.95%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.19
Upside: +5.71%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $74.38
Upside: +38.48%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $78.21
Upside: -10.50%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $313.08
Upside: -28.77%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $86.02
Upside: -11.65%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.43
Upside: +5,044.03%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $168.21
Upside: -28.07%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.78
Upside: +403.60%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $18.94
Upside: +137.59%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.49
Upside: +1.19%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.29
Upside: +331.24%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $8.58
Upside: +179.72%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $393.55
Upside: -12.34%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $91.46
Upside: +42.14%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $256.43
Upside: -10.31%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $18.43
Upside: +8.52%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $52.17
Upside: +62.93%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $58.60
Upside: +27.99%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $255.16
Upside: -3.98%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $30.39
Upside: +104.01%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $119.47
Upside: +75.78%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $11.08
Upside: +8.30%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $86.33
Upside: +44.79%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $106.53
Upside: -53.06%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $533.71
Upside: -60.65%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $45.75
Upside: +109.84%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.96
Upside: +257.14%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $170.86
Upside: +55.68%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.78
Upside: +63.60%